Author + information
- Received February 1, 2018
- Revision received August 8, 2018
- Accepted August 13, 2018
- Published online December 17, 2018.
- Takehiro Kimura, MDa,
- Shin Kashimura, MDa,
- Takahiko Nishiyama, MDa,
- Yoshinori Katsumata, MDa,
- Kohei Inagawa, MDb,
- Yukinori Ikegami, MDb,
- Nobuhiro Nishiyama, MDa,
- Kotaro Fukumoto, MDa,
- Yoko Tanimoto, MDb,
- Yoshiyasu Aizawa, MDa,
- Kojiro Tanimoto, MDb,
- Keiichi Fukuda, MDa and
- Seiji Takatsuki, MDa,∗ ()
- aDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan
- bDepartment of Cardiology, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan
- ↵∗Address for correspondence:
Dr. Seiji Takatsuki, Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Objectives This randomized study compared uninterrupted rivaroxaban therapy with warfarin therapy as prophylaxis against catheter ablation (CA)-induced asymptomatic cerebral infarction (ACI) and identified the risk factors of rivaroxaban.
Background The reported incidence of ACI during CA for atrial fibrillation (AF) remains at 10% to 30%, and periprocedural oral anticoagulation could affect this incidence.
Methods Patients with nonvalvular AF undergoing radiofrequency CA were randomly assigned to receive either uninterrupted rivaroxaban or warfarin as periprocedural anticoagulation therapy. CA was performed after at least 1 month of adequate anticoagulation. Cerebral magnetic resonance imaging (MRI) was performed within 2 weeks before and 1 day after CA to detect ACI.
Results A total 132 patients were enrolled; 127 (median: 60.0 years of age; 83.5% males; 64.6% incidence of paroxysmal AF) complied with the study protocol and were analyzed; 64 patients received rivaroxaban, and 63 patients received warfarin. The rates of CA-induced ACI in the rivaroxaban group (15.6% [10 of 64 patients]) were similar to those in the warfarin group (15.9% [10 of 63 patients]; p = 1.000). No thromboembolic events developed; no differences in major or nonmajor bleeding rates were observed between the 2 drug groups (3.1% vs. 1.6%, respectively, or 18.8% vs. 19.0%, respectively). Multiple regression analysis indicated that the presence of deep and subcortical white matter hyperintensity (p = 0.002; odds ratio [OR]: 5.323) and the frequency of cardioversions (p = 0.016; OR: 1.250) were associated with the incidence of ACI.
Conclusions No notable differences were found between the incidence of CA-induced ACI in the rivaroxaban group and that in the warfarin group in this randomized study.
- asymptomatic cerebral infarction
- atrial fibrillation
- cardiac magnetic resonance imaging
Supported by Bayer Yakuhin, Ltd., Japan. All authors have reported that they have no relationships with industry relevant to the contents of this paper to disclose.
All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Clinical Electrophysiology author instructions page.
- Received February 1, 2018.
- Revision received August 8, 2018.
- Accepted August 13, 2018.
- 2018 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.